### Identification of clinically-relevant genetic alterations in 1

### uveal melanoma using RNA sequencing 2

3 R.J.	Nell <sup>1</sup>
--------	-------------------

- 4 M. Versluis<sup>1</sup>
- D. Cats<sup>4</sup> 5
- 6 H. Mei<sup>4</sup>
- 7 R.M. Verdijk<sup>2,3</sup>
- 8 W.G.M. Kroes<sup>5</sup>
- 9 G.P.M. Luyten<sup>1</sup>
- 10 M.J. Jager<sup>1</sup>
- 11 P.A. van der Velden<sup>1\*</sup>
- 12
- 13 <sup>1</sup> Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
- 14 <sup>2</sup> Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
- 15 <sup>3</sup> Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands.
- <sup>4</sup> Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the 16
- Netherlands. 17
- 18 <sup>5</sup> Department of Clinical Genetics, Leiden University Medical Center, Leiden, the
- 19 Netherlands.
- 20
- 21 \* Corresponding author, Department of Ophthalmology, Leiden University Medical Center,
- 22 PO Box 9600, 2300 RC Leiden, The Netherlands.
- 23

#### 24 Acknowledgements

- 25 This study is supported by the European Union's Horizon 2020 research and innovation
- 26 program under grant agreement number 667787 (UM Cure 2020, Rogier J. Nell). We thank
- 27 Ronald van Eijk (Department of Pathology, Leiden University Medical Center, Leiden, the
- Netherlands) for his help with the *BAP1* DNA sequencing experiments. This work is partly 28
- 29 based upon data generated by The Cancer Genome Atlas (TCGA) Research Network:
- 30 https://www.cancer.gov/tcga.

# 31 Abstract

### 32 Introduction

- 33 Uveal melanoma is a lethal intraocular tumour, in which the presence of certain genetic
- 34 alterations correlates with the risk of metastatic dissemination and patient survival. RNA data
- 35 is typically used to transcriptionally characterise tumours and their micro-environment. In this
- 36 study, we tested the detectability of all key genetic alterations in uveal melanoma from RNA
- 37 sequencing data.
- 38

### 39 Methods

- 40 Cohort-wide gene expression profiling was used to classify tumours at the transcriptional
- 41 level. In individual samples, copy number alterations affecting chromosomes 3 and 8q were
- 42 analysed by measuring expressed allelic imbalances of heterozygous common single
- 43 nucleotide polymorphisms. Mutations in GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1
- 44 and *EIF1AX* were identified by screening of hotspot regions and by evaluating their
- 45 transcriptional effects. All findings were cross-validated with DNA-derived data in a training
- 46 cohort of 80 primary uveal melanomas studied by The Cancer Genome Atlas (TCGA)
- 47 initiative, and in five prospectively analysed cases from our institution.
- 48

## 49 Results

- 50 Unsupervised gene expression profiling strongly correlated to the presence of chromosome
- 51 3 alterations, but was not reliable in identifying other (clinically-)relevant genetic alterations.
- 52 However, the presence of both chromosome 3 and 8q copy number alterations could be
- 53 successfully inferred from expressed allelic imbalances in most tumours. The majority of
- 54 mutations were adequately recognised at the RNA level by their nucleotide changes (all
- 55 genes), alternative splicing around the mutant position (*BAP1*) and transcriptome-wide
- aberrant splice junction usage (*SF3B1*). Notably, in the TCGA cohort we detected previously
- 57 unreported mutations in *BAP1* (n=3) and *EIF1AX* (n=5), that were missed by the original
- 58 DNA sequencing. In our prospective cohort, all mutations and copy number alterations were
- 59 successfully identified at the RNA level by combining the described approaches.
- 60

## 61 Conclusion

- 62 In addition to providing gene expression levels and profiles, RNA from uveal melanomas
- 63 presents insights into the expressed tumour genotype and its phenotypic consequences.
- 64 Such complete analysis of transcriptional data may augment or even substitute current DNA-
- based approaches, and has potential applicability in both research and clinical practice.

#### Introduction 66

67 Uveal melanoma is a lethal intraocular tumour characterised by a high metastatic rate and

- 68 limited treatment options once disseminated [1]. In contrast to most other malignancies, it
- presents as a relatively simple genetic disease with a low mutational burden and limited 69
- 70 number of structural variants [2, 3]. Practically all tumours harbour a mutually-exclusive
- 71 mutation in GNAQ. GNA11. CYSLTR2 or PLCB4, which activates the  $G\alpha_{\alpha}$  signalling
- 72 pathway [4-7]. Most uveal melanomas also carry a so-called BSE (BAP1, SF3B1 or EIF1AX)
- 73 mutation [2, 8-10]. Copy number losses of chromosome 3 and increases of chromosome 8q
- 74 are the most prevalent structural alterations, and occur in specific combinations together with
- 75 the BSE mutations. These various molecular subtypes have been associated with distinct
- 76 gene expression profiles (GEP) and are differentially correlated to the risk of early metastatic
- 77 dissemination and consequent patient survival (Table 1).
- 78

79 The prognostic value of genetic alterations in uveal melanoma has been recognised for more

- 80 than two decades. Traditionally, copy number alterations were studied using cytogenetic
- 81 techniques, such as karyotyping, fluorescence in situ hybridisation, multiplex ligation-
- 82 dependent probe amplification and array genotyping [11-15]. Technical advancements
- 83 enabled genome-wide analyses by next-generation sequencing and led to the discovery of
- recurrent mutations [2, 8-10]. Nowadays, (targeted) sequencing can be used to detect all 84
- 85 relevant alterations – both copy number alterations and mutations – in one single analysis
- 86 [16, 17].
- 87

In addition to these DNA-based approaches, several studies have identified clinically-88 89 relevant transcriptional subtypes of uveal melanoma [18-21]. Most commonly, tumours are 90 divided into class I or II based on their bulk GEP. This classification can be established using 91 dimensionality reduction and sample clustering techniques of total RNA expression data, or 92 by evaluating expression variation in a selection of genes. Intriguingly, this transcriptional 93 classification of tumours is known to strongly correlate with the presence of genetic 94 alterations affecting chromosome 3 (**Table 1**). Given that part of the bulk GEP may be 95 derived from admixed non-malignant cells, such as tumour-infiltrating immune cells, RNA 96 data can also provide insights into the tumour microenvironment of uveal melanomas [22, 97 23].

98

99 More recently, the presence and consequences of genetic alterations at the transcriptional 100 level have gained interest in the context of uveal melanoma. Mutations in SF3B1, a gene

101 encoding for a core component of the cell's splicing machinery, were found to lead to a

102 recurrent profile of aberrant splice junction usage [2, 24]. As another example, in three large-103 scale genomic studies, a variety of complex BAP1 alterations were only identified after using 104 RNA sequencing data in addition to DNA-derived data [21, 25, 26]. Finally, CYSLTR2 mutant 105 uveal melanomas recurrently showed silencing of the wild-type allele and preferential 106 expression of the p.L129Q mutation [27]. These examples emphasise the value of 107 investigating RNA in addition to DNA to identify the presence and consequences of certain 108 genetic alterations. 109 110 In this study, we apply various bioinformatic approaches to detect all key genetic alterations in uveal melanoma by only using tumour-derived RNA sequencing data. Cohort-wide GEP is 111 112 used to identify class I and II tumours. In individual samples, copy number alterations are 113 analysed by measuring expressed allelic imbalances of heterozygous common single 114 nucleotide polymorphisms (SNPs). Mutations are identified by screening of hotspot regions

and by evaluating their transcriptional effects. Our findings are cross-validated with DNA-

116 derived data in a training cohort of 80 primary uveal melanomas originally studied by The

117 Cancer Genome Atlas (TCGA) initiative, and in five prospectively analysed cases from our

118 institution.

# 119 Methods

## 120 Collection and analysis of retrospective cohort

- 121 RNA sequencing files from the 80 primary uveal melanomas studied by the TCGA [13] were
- downloaded from the NCI Genomic Data Commons data portal (GDC;
- 123 <u>https://portal.gdc.cancer.gov</u>). After reconversion to FASTQ files using samtools (version
- 124 1.1), the reads were aligned using STAR (version 2.5.3a) to human reference genome
- 125 GRCh38. Gene counts were generated using htseq-count (version 0.6.0) and annotated with
- 126 Ensembl (version 87). DESeq2 (version 1.30.0) was used for variance stabilising
- 127 transformation of the count data, which formed the input for the uniform manifold
- 128 approximation and projection (UMAP) analysis. An expression signature of 200 genes
- 129 characterising the two visually separated clusters was identified using ClaNC, and was used
- to classify tumours as 'class I' or 'class II' based on the relative expression of chromosome 3
- 131 genes (i.e. high or low, respectively).
- 132
- 133 The aligned RNA sequencing files were analysed for variants using VarScan (version 2.3),
- 134 which were annotated using snpEff/snpSift (version 5.1) according to dbSNP (version 151).
- 135 Only heterozygously and highly expressed common SNPs (flagged as 'common', total
- 136 number of reads > 40, number of reference reads > 2, number of alternate reads > 2) were
- 137 included in the downstream analysis. For all SNPs, the fractions alternate reads of total
- 138 reads were visualised according to their chromosomal positions. Segmentation was
- 139 performed manually. RNA-derived allelic (im)balances were compared to DNA-measured
- 140 copy number information determined from Affymetrix SNP 6.0 arrays, available from the
- 141 Pan-Cancer Atlas initiative [28].
- 142
- 143 All aligned RNA sequencing files were further screened for (hotspot) mutations in GNAQ
- 144 (p.Q209, p.R183 and p.G48), *GNA11* (p.Q209, p.R183), *CYSLTR2* (p.L129), *PLCB4*
- 145 (p.D630), *EIF1AX* (entire gene), *SF3B1* (exon 14) and *BAP1* (entire gene) using freebayes
- 146 (version 1.3.6), and via manual inspection using the Integrative Genomics Viewer (version
- 147 2.8.10). The presence of mutations was compared to those detectable in aligned DNA
- 148 sequencing files generated by exome-captured sequencing (n=80) or low-pass whole-
- 149 genome sequencing (n=51) downloaded from the GDC data portal.
- 150
- 151 The bioinformatic analyses were carried out using R (version 4.0.3) and RStudio (version
- 152 1.4.1103). All custom scripts are available via <u>https://github.com/rjnell/um-rna</u>.
- 153

### 154 Collection, isolation and analysis of prospective cohort

- Five snap-frozen primary uveal melanoma specimens were collected from the biobank of the
  Department of Ophthalmology, Leiden University Medical Center (LUMC). These samples
  were originally obtained from patients treated by an enucleation in the LUMC. This study
  was approved by the LUMC Biobank Committee and Medisch Ethische Toetsingscommissie
  under numbers B14.003/SH/sh and B20.026/KB/kb.
- 160

161 RNA from all specimens (25x 20µm sections) was isolated using the QIAamp RNeasy Mini 162 Kit (Qiagen, Hilden, Germany), following the manufacturer's instructions. 100 ng of RNA per 163 sample was sequenced by GenomeScan (Leiden, the Netherlands). Sample preparation 164 was performed using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New 165 England Biolabs, Ipswich, USA) according to the NEB #E7240S/L protocol. In short, mRNA 166 was isolated from total RNA using oligo-dT magnetic beads. After fragmentation of the 167 mRNA, cDNA synthesis was performed and used for ligation with the sequencing adapters 168 and PCR amplification. Quality and yield were measured with the Fragment Analyzer 169 (Agilent, Santa Clara, USA). Next, clustering and DNA sequencing was performed using the 170 cBot and HiSeg 4000 (Illumina, San Diego, USA) according to the manufacturer's protocols. 171 HiSeq control and image analysis, base calling and guality check were carried out using 172 HCS (version 3.4.0), the Illumina data analysis pipeline RTA (version 2.7.7) and bcl2fastq 173 (version 2.17). The raw sequencing files underwent the same alignment and analysis 174 pipeline as the TCGA data files to perform GEP clustering and infer copy number alterations 175 and mutations.

- 177 DNA from uveal melanomas (25x 20µm sections) was isolated with the QIAmp DNA Mini Kit 178 (Qiagen) according to the manufacturer's instructions. Digital PCR was performed to 179 measure the copy number values of chromosome 3 and 8g and to confirm mutations in 180 GNAQ, GNA11, EIF1AX and SF3B1. These experiments were carried out using the QX200 181 Droplet Digital PCR System (Bio-Rad Laboratories, Hercules, USA) following established 182 protocols [22, 27, 29-31], and two new assays listed in Supplementary Table 1. The 183 presence and pathogenicity of BAP1 alterations was confirmed by targeted Sanger or next-184 generation sequencing and an immunohistochemical staining, both performed as routine diagnostic analyses in two ISO accredited laboratories (Departments of Clinical Genetics 185 186 and Pathology, LUMC) [16, 32].
- 187

#### Results 188

#### 189 Estimation of genetic alterations via cohort-wide gene expression profiling

190 The RNA-derived classification of primary uveal melanomas into GEP class I or II is 191 originally based on unsupervised clustering of transcriptome-wide expression data into two 192 groups [19, 20]. Concordantly, a dimensionality reduction analysis (UMAP) successfully 193 divided the TCGA tumours (n=80) into two main clusters based on their total transcriptional 194 diversity (Figure 1A). To investigate expression patterns underlying this subdivision, we 195 inferred a signature of 200 genes characterising the two clusters. The largest proportion 196 (82/200, 41%) of these genes were located on chromosome 3 (Figure 1B and 197 Supplementary Table 2), with systematically lower levels of expression in one cluster of 198 tumours (n=40, marked as GEP class II) relative to the other (n=40, marked as GEP class I). 199 This classification almost completely overlapped with the true DNA-determined copy number 200 status of chromosome 3: 40/40 GEP class II tumours demonstrated loss of this chromosome 201 (i.e. monosomy, or isodisomy in polyploid melanomas), compared to 3/40 GEP class I 202 tumours (Figure 1C and Supplementary Table 3). The three discordant cases were the 203 only tumours showing arm-level variation of chromosome 3 loss (n=2) or an unusual trisomy 204 3 in the context of polyploidy (n=1, **Supplementary Figure 1A and B**). In line with the frequent co-occurrence of chromosome 3 copy number losses and BAP1 alterations, 205 206 mutations in BAP1 were present in 40/40 GEP class II and 0/40 GEP class I tumours

- 207 (Figure 1C and Supplementary Table 3).
- 208

209 In contrast, cohort-wide GEP clustering did not specifically overlap with the presence of

- 210 chromosome 8q copy number changes or other mutations, even not after specifying the
- 211 analysis to class I or II tumours only (Figure 1C and Supplementary Figure 2). These
- 212 observations suggest that alternative approaches are needed to infer all (clinically-)relevant
- 213 genetic alterations from RNA data.
- 214

#### 215 Identification of copy number alterations via RNA-expressed allelic imbalances

216 To detect chromosomal copy number alterations in individual tumours, we proceeded by 217 measuring regional allelic imbalances in the RNA sequencing data. For this goal, highly 218 expressed heterozygous common SNPs were identified and their so-called B-allele fractions 219 (BAFs) were visualised according to their chromosomal positions. These values refer to the 220 measured expression of one allele compared to the total expression of both alleles. Under 221 copy number neutral conditions, two alleles - and thus both SNP variants - are equally

222 abundant, resulting in BAFs of ~50% (Figure 2A). In contrast, a chromosomal loss, such as 223 monosomy 3, typically leads to BAFs close to  $\sim$ 0% and  $\sim$ 100%, as it is caused by an 224 (almost) complete loss of one of the two alleles ('loss of heterozygosity', Figure 2B). Using 225 this approach, we were able to correctly identify disomic tumours (n=40, with preserved 226 balanced expression) and tumours with (partial) loss of chromosome 3 (n=39, showing 227 imbalanced expression) from the RNA sequencing data in 79/80 (99%) cases of the TCGA 228 cohort (Figure 2C and Supplementary Table 3). The only conflicting case was the one 229 presenting with an unusual trisomy 3 in the context of polyploidy, which was also 230 characterised by an allelic imbalance (Supplementary Figure 1B). 231 232 This latter case illustrates that, similar to chromosomal losses, copy number increases 233 typically also lead to allelic imbalances. A gain, such as of chromosome 8q (or chromosome 234 3 in the discordant case described above), is usually the result of an extra copy of one allele. 235 leading to BAFs around ~67% and ~33% (Figure 2A). Larger amplifications mostly originate 236 from several copies of one allele (with BAFs >67% and <33%, Figure 2B). On the other 237 hand, amplifications derived from extra copies of both alleles or subclonal alterations result 238 in BAFs closer to 50% and may be more difficult to recognise (Supplementary Figure 1C). 239 In the TCGA cohort, chromosome 8q allelic imbalances were detected in the RNA 240 sequencing data of 53 tumours, which all had a DNA-confirmed gain or amplification of 241 chromosome 8q. The remaining 27 cases lacked measurable BAF deviations, and could be 242 explained by a disomy 8q (n=21) or a copy number increase of both alleles (n=6). In 243 aggregate, the presence or absence of any 8g alteration was correctly identified from RNA 244 sequencing data in 74/80 (93%) of these uveal melanomas (Figure 2C and Supplementary 245 Table 3).

246

247 Of note, depending on the number of informative SNPs and their clonality in individual

248 tumours, regional allelic imbalances involving other chromosomes were also successfully

- identified by this approach (Figure 2A and B). 249
- 250

#### 251 RNA-based identification of $G\alpha_{\alpha}$ and BSE mutations

252 Next, we aimed to identify the mutational status of individual uveal melanomas at the 253 transcriptional level (Figure 3A and Supplementary Table 3).  $G\alpha_{\alpha}$  signalling mutations are 254 known to occur at a selected number of hotspots (p.G48, p.R183 and p.Q209 for GNAQ and 255 GNA11, p.L129 for CYSLTR2 and p.D630 for PLCB4 [4-7]), allowing for a targeted analysis 256 of RNA sequencing data (Figure 3B). Though, due to a lack of sequencing reads covering 257 the mutant positions, DNA-confirmed GNAQ mutations could not be adequately detected in

258 the RNA data of four cases (**Supplementary Figure 2A**). Still, the  $G\alpha_{a}$  mutations were 259 correctly identified in the remaining 74/78 (95%) mutant uveal melanomas (Figure 3A and 260 Supplementary Table 3).

261

262 BAP1 alterations are typically inactivating mutations (or deletions) that can be present 263 throughout the complete BAP1 gene. This challenges the identification of all alterations 264 using conventional sequencing [25, 26]. In the TCGA cohort of uveal melanomas, it was 265 earlier shown that various complex (intronic) BAP1 alterations can be identified by the use of 266 RNA sequencing [21, 25]. Importantly, exonic missense and nonsense mutations are also 267 detectable at the transcriptional level: directly via their nucleotide changes, or indirectly via 268 observed alternative splicing events such as (partial) intron retention or exon skipping 269 (Figure 3C). Due to a low number of mutant RNA sequencing reads, two mutations were 270 only identified at the DNA level (Supplementary Figure 2A). Taken together, 38/40 (95%) 271 BAP1 mutations could be detected via RNA sequencing (Figure 3A and Supplementary 272 Table 3), including three mutations that had remained unrecognised in previous studies 273 (p.W196X in VD-A8KM, a deletion involving the start of exon 1 in V4-A9ES, and a frameshift

- 274 deletion involving exon 8 in WC-A883, Figure 3C and Supplementary Figure 2B). 275
- 276 SF3B1 mutations in uveal melanomas are predominantly found in exon 14, with most of
- 277 them affecting positions p.R625 or p.K666 [2, 9, 10, 24]. We successfully identified 14/15
- 278 (93%) DNA-confirmed mutations by nucleotide variation in the RNA sequencing data of the
- 279 TCGA cohort (Figure 3A, 3D and Supplementary Table 3), with again a limited number of
- 280 reads at the mutant position in the discordant tumour (Supplementary Figure 2A).
- 281 However, alternative splicing was found in all 15/15 (100%) mutant tumour samples (Figure
- 282 **3E**), corroborating the differences between *SF3B1* mutant and wild-type uveal melanomas at 283 the RNA level [24].
- 284

285 EIF1AX mutations mainly affect the N-terminal region of the gene, spanning the first two 286 exons with a total of fifteen amino acids [10]. In the TCGA dataset, we detected the 287 presence of a DNA-confirmed *EIF1AX* mutation in the RNA of 9/10 tumours, with – similar to 288 the missed GNAQ mutation in the same tumour – a lack of sequencing reads explaining the 289 discordant sample (Supplementary Figure 2A). However, we also observed that there was practically no coverage of exon 1 in the exome-captured DNA sequencing data, and none of 290 291 the TCGA tumours was known to have an exon 1 mutation [21]. By analysing the 292 (uncaptured) RNA sequencing data (Figure 3D), we identified expressed exon 1 mutations 293 in five TCGA cases (p.P2H in VD-AA8M, p.P2L in YZ-A983, p.P2R in V4-A9EH, p.K3N in

294 WC-A87T, and p.N4S in VD-AA8Q). All these tumours further presented with disomy of

chromosomes 3 and 8q and lacked mutations in *SF3B1* or *BAP1*, in line with the typical

296 genotype of *EIF1AX*-mutant tumours. For two cases, low-pass whole genome sequencing

297 was available and confirmed both mutations (Supplementary Figure 2C). Taken together,

298 14/15 (93%) *EIF1AX* mutations were successfully identified at the RNA level, including five

299 previously missed with DNA-based exome sequencing (**Figure 3A and Supplementary** 

- 300 **Table 3**).
- 301

### 302 **Prospective validation of RNA-based detectability of genetic alterations**

303 Finally, we aimed to prospectively validate all beforementioned techniques in an

independent cohort. For this goal, we performed RNA sequencing of five primary uveal

305 melanoma specimens obtained after enucleation in our hospital (Figure 4 and

**Supplementary Table 4**). The presence of chromosome 3 and 8q copy number alterations,

and  $G\alpha_q$  and BSE mutations was confirmed at the DNA level using digital PCR and targeted

sequencing, and – for BAP1 – at the protein level using immunohistochemistry.

309

310 Although the number of tumours in our cohort was too low to reliably determine the GEP

311 classification based on unsupervised clustering (**Figure 4A**), three tumours were found to be

312 GEP class I and two tumours were GEP class II upon evaluation of our TCGA-based 200-

313 gene expression signature. This classification matched with the loss of heterozygosity of

314 chromosome 3 in the RNA sequencing data (exemplified in **Figure 4B**). Additionally, three

315 tumours showed allelic imbalances of chromosome 8g. The presence of all these presumed

316 copy number alterations could be successfully validated at the DNA level.

317

318 Regarding the  $G\alpha_{\alpha}$  mutations, all five tumours expressed one hotspot mutation in GNAQ 319 (n=4) or GNA11 (n=1, Figure 4B). Next, the RNA data demonstrated the presence of BSE 320 mutations in BAP1 (n=2), SF3B1 (n=2) and EIF1AX (n=1). The BAP1 mutations caused 321 RNA-detectable nucleotide variation as well as altered splicing around the mutated sites, 322 showing high similarities to TCGA tumours with comparable mutations (Figure 4C). The 323 tumours with the SF3B1 p.R625 hotspot mutations were the ones demonstrating SF3B1-324 associated aberrant splicing (Figure 4D). One tumour carried an EIF1AX mutation affecting 325 exon 2. All mutations could be verified at the DNA level. Additionally, the presence and 326 pathogenicity of the BAP1 alterations was supported by a negative (n=2) or positive (n=3)327 BAP1 nuclear staining (**Supplementary Table 4**). 328

329 Taken together, all measured copy number alterations and mutations were correctly

identified in the RNA sequencing data of the five uveal melanomas.

# 331 **Discussion**

Uveal melanoma is characterised by a number of prognostically-relevant combinations of
genetic alterations, that are mostly measured at the DNA level. In this study, we tested
whether these alterations could also be detected at the transcriptional level using RNA
sequencing data. This identification of mutations and copy number alterations was crossvalidated with DNA-based techniques in both a retrospective cohort of 80 TCGA tumours
and five prospectively analysed uveal melanomas from our own cohort.

339 First of all, we explored the indirect detectability of genetic alterations via unsupervised GEP 340 clustering, a commonly-used procedure in the context of classifying uveal melanoma. Our 341 analysis revealed – in line with earlier studies – two main groups of tumours which 342 overlapped with the absence or presence of chromosome 3 alterations (complete 343 chromosomal loss and BAP1 mutation, Figure 1 and 4A). Indeed, a large number of genes 344 on chromosome 3 was expressed systematically lower in bulk RNA upon loss of this 345 chromosome. However, GEP clustering was influenced by the extent of chromosome 3 loss (i.e. partial losses were not identified) and could not be used to specify the exact BAP1 346 347 mutation. It also did not identify chromosome 8g copy number alterations or any of the other 348 recurrent and relevant mutations, such as those in SF3B1 and EIF1AX. As a further 349 drawback, the GEP approach intrinsically relies on differences observed within a cohort, 350 between multiple tumours. This makes this analysis less applicable to separate tumours, as 351 it always requires a comparison to other samples (or 'normal' values) to identify any variation. For this reason, we further focussed on alternative approaches applicable to data 352 353 of individual uveal melanomas.

354

355 To better identify chromosomal alterations, we measured regionally-abundant allelic imbalances of heterozygous common SNPs detectable in RNA data (Figure 2). This 356 357 approach has several similarities to a DNA-based methodology we presented and discussed 358 recently [31]. Based on (partial) copy number losses of chromosome 3, expressed loss of 359 heterozygosity could be observed at the transcriptional level and turned out to be an 360 excellent marker for this genetic event. The other way round, chromosome 8q copy number 361 increases, predominantly mono-allelic gains or amplifications, were also readily detected by 362 allelic imbalances present in RNA. Advantageously, by selecting SNPs known to be 363 frequently heterozygous in the population, no patient-matched genotype information was 364 required.

366 To detect BSE mutations at the RNA level, all mutational hotspot regions were screened and 367 possible transcriptional consequences of various alterations (i.e. alternative splicing) were 368 evaluated (Figure 3). Although a small number of mutations were missed due to insufficient 369 sequencing coverage, the large majority was successfully detected in the RNA data. 370 Interestingly, this included three additional BAP1 mutations and five EIF1AX mutations in the 371 TCGA cohort that were previously unrecognised as part of the respective genes were not or 372 not sufficiently covered by the exome-captured DNA sequencing. Clinically, these alterations 373 are prognostically relevant and not to be missed in any routine mutational screening of a 374 uveal melanoma, substantiating complete coverage in any (targeted) sequencing panel. It is 375 also essential that these alterations are known and being taken into account when analysing 376 mutation data from these TCGA tumours in a research setting.

377

378 Though most mutations were directly recognised from nucleotide changes visible in the RNA 379 sequencing reads, a number of BAP1 mutations were identified via unusual splicing events 380 within this gene (Figure 3C and 4C). In some tumours, the splice site disruption may be 381 directly caused by the mutation being located near a regular exon-intron boundary, or the 382 mutation introducing a novel splice site. Other tumours showed evidence of 'nonsense-383 associated alternative splicing': (partial) exon skipping or intron retention, apparently in 384 response to the premature translation-termination codons introduced by nonsense or 385 frameshift mutations. In contrast to nonsense-mediated decay, in-frame alternative splicing 386 bypassing the original mutation might encode for a protein with saved functionalities, even 387 though the mutation is predicted to be truncating and highly pathogenic [33, 34]. Our 388 observations – possibly explainable by these phenomena, but yet to be followed up at a 389 functional level – further contribute to the notorious complexity of BAP1 alterations and their 390 biological consequences [16, 17, 35-37].

391

392 Critically, our current study is limited by its low number of prospectively validated cases from 393 independent cohorts. Still, the cross-validation in a total of 85 tumours (i.e. the TCGA and 394 our own cohort combined) strongly suggests that most relevant alterations in uveal 395 melanoma can be detected at the transcriptional level, especially when various bioinformatic 396 approaches are combined. This indicates that RNA sequencing data, newly or 397 retrospectively collected for gene expression analysis, may be mined for genetic alterations 398 without the need to perform additional DNA-based measurements. Moreover, it may allow 399 researchers to study genotype-phenotype relations in the same tumour specimen in more 400 detail. This is particularly interesting in the context of measuring genetic heterogeneity next 401 to transcriptional heterogeneity, for example using multiregional or single-cell RNA 402 sequencing. Thirdly, the detectability of genetic alterations in the RNA of uveal melanomas

403 may provide the rationale to study (cell-free) RNA from liquid biopsies, which already404 showed potential in other types of cancer [38-41].

405

406 In a follow-up study, our evaluations may be extended to other genetic alterations in uveal 407 melanoma. Besides chromosome 3 and 8q, (partial) copy number alterations affecting 408 chromosome 1, 6 and 16 are recurrently present and - although not extensively validated -409 were already correctly observed as allelic imbalances in some of our tumours (Figure 2 and 410 Supplementary Figure 1). Additionally, mutations in splicing factor SRSF2, which seem to 411 form a rare alternative to SF3B1 mutations [21, 42], might be recognised in the RNA 412 sequencing reads or by its own signature of alternative splicing. Moreover, it would be 413 therapeutically relevant to evaluate alterations involving MBD4. Biallelic inactivation of this 414 gene (via a mutation and copy number loss of its locus on chromosome 3) has been 415 identified as a rare cause of CpG>TpG hypermutation in uveal melanoma, conferring unique 416 sensitivity to immunotherapy [43, 44]. Next to identifying mutations at the RNA level, 417 additional evidence for MBD4 inactivation can be found in an unusually high total mutational burden, which might also be inferred from RNA sequencing data [45]. Finally, our 418 419 methodologies might be valuable beyond the field of uveal melanoma, and it would be 420 interesting to evaluate these in other types of cancer. 421

422 In conclusion, we developed and applied a variety of bioinformatic approaches showing that 423 transcriptional data – in addition to providing gene expression levels and profiles – forms a 424 rich source of (clinically-)relevant genetic information in uveal melanoma. Via RNA, valuable 425 insights could be obtained into the expressed genotype and its phenotypic consequences, 426 but this also demonstrated the vulnerabilities of an (insufficiently) targeted DNA 427 measurement. As illustrated by the identification of previously unreported mutations in the 428 thoroughly studied TCGA cohort, and the successful prospective analysis of tumours of our 429 own cohort, the analysis of transcriptional data may augment or even substitute current 430 DNA-based approaches, and has potential applicability in both oncological research and clinical practice. 431

# 432 **Table**

## 433 Table 1

GEP	Mutations	Copy number alterations	Risk to (early) metastasis
Class I	Gα <sub>q</sub> + <i>EIF1AX</i>		Low
	Gα <sub>q</sub> + <i>SF3B1</i>	+8q	Intermediate
Class II	Gα <sub>q</sub> + <i>BAP1</i>	-3, +8q	High

434

435 Summary of three most typical combinations of GEP classification, mutations, chromosomal

436 copy number alterations and their correlation to the risk of (early) metastatic dissemination

437 [1].

### **Figures** 439

#### 440 Figure 1



- 441 442
- Cohort-wide gene expression profiling (GEP) to estimate the presence of genetic alterations 443
- 444 in our training cohort of uveal melanomas studied by The Cancer Genome Atlas (n=80).
- 445 (A) Two-dimensional uniform manifold approximation and projection (UMAP) analysis to
- 446 identify two clusters of tumours: GEP class I and II.
- (B) Chromosomal location of signature genes characterising the two clusters. 447
- 448 (C) Relative gene expression levels of signature genes characterising the two clusters in
- relation to the genetic alterations present per individual tumour. 449
- 450
- 451

### 452 Figure 2





455 RNA-inferred allelic imbalances in relation to DNA-confirmed copy number alterations.

456 (A) Example of a tumour showing balanced expression of chromosome 3, but imbalanced

457 expression of chromosome 8q, in line with a disomy 3 and copy number alteration of

chromosome 8q. Additionally, alterations affecting chromosome 6p, 6q and 17q (partial) arecorrectly identified.

460 (B) Example of a tumour showing imbalanced expression of both chromosome 3 and 8q, in

461 line with copy number alterations of the two chromosomes. Additionally, an alteration

462 affecting chromosome 6p (partial) is correctly identified.

463 (C) Overview of RNA- and DNA-derived observations in the 80 TCGA tumours.

# 465 **Figure 3**



- 468 Detectability of mutations via RNA sequencing data in our training cohort of uveal
- 469 melanomas studied by TCGA (n=80).
- 470 (A) Summary of detected mutations in comparison to findings in exome-captured DNA
- 471 sequencing.
- 472 (**B**) Examples of detected  $G\alpha_q$  signalling mutations in RNA sequencing data.

- 473 (C) Examples of detected *BAP1* mutations in RNA sequencing data: although some were
- 474 identified directly via nucleotide variation, others showed alternative splicing around the
- 475 mutant position.
- 476 (**D**) Example of detected *SF3B1* mutation in RNA sequencing data.
- 477 (E) Analysis of a signature of alternative splicing to identify *SF3B1* mutant tumours.
- 478 (F) Examples of detected *EIF1AX* mutations in RNA sequencing data.
- 479

480 Figure 4



<sup>481</sup> 

- 482 Analysis of our prospective cohort of uveal melanomas (n=5).
- 483 (A) Two-dimensional uniform manifold approximation and projection (UMAP) analysis of

p.D68 splicing

- cohort-wide gene expression profiling (GEP) and application of TCGA-derived GEP-classifier 484
- in relation to the RNA- and DNA-based detectability of genetic alterations. 485
- (B) Representative example of RNA-inferred allelic (im)balances to identify chromosomal 486
- 487 alterations. In this tumour, imbalanced expression of genes of chromosome 3 correctly
- 488 indicates the presence of a copy number alteration affecting this chromosome. In contrast,
- 489 no imbalance is observed on chromosome 8q, in line with a disomy 8q.
- 490 (C) BAP1 alterations (mutations and mutation-associated alternative splicing) as observed in
- the RNA sequencing data. 491

p.I226Tfs\*4 (c.677delT)

+ splicing

492 (D) Analysis of a signature of alternative splicing to identify SF3B1 mutant tumours.

All rights reserved. No reuse allowed without permission.

# 493 **References**

- 494 1. Jager, M.J., et al., *Uveal melanoma*. Nat Rev Dis Primers, 2020. **6**(1): p. 24.
- 495 2. Furney, S.J., et al., SF3B1 mutations are associated with alternative splicing in uveal
  496 melanoma. Cancer Discov, 2013. 3(10): p. 1122-1129.
- 497 3. Royer-Bertrand, B., et al., Comprehensive Genetic Landscape of Uveal Melanoma by Whole 498 Genome Sequencing. Am J Hum Genet, 2016. 99(5): p. 1190-1198.
- 499 4. Van Raamsdonk, C.D., et al., *Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.* Nature, 2009. **457**(7229): p. 599-602.
- 501 5. Van Raamsdonk, C.D., et al., *Mutations in GNA11 in uveal melanoma.* N Engl J Med, 2010. **363**(23): p. 2191-9.
- 503 6. Johansson, P., et al., *Deep sequencing of uveal melanoma identifies a recurrent mutation in* 504 *PLCB4.* Oncotarget, 2016. **7**(4): p. 4624-31.
- 505 7. Moore, A.R., et al., *Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.* Nat Genet, 2016. **48**(6): p. 675-80.
- 5078.Harbour, J.W., et al., Frequent mutation of BAP1 in metastasizing uveal melanomas. Science,5082010. **330**(6009): p. 1410-3.
- 5099.Harbour, J.W., et al., Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal510melanoma. Nat Genet, 2013. 45(2): p. 133-5.
- 51110.Martin, M., et al., Exome sequencing identifies recurrent somatic mutations in EIF1AX and512SF3B1 in uveal melanoma with disomy 3. Nat Genet, 2013. 45(8): p. 933-6.
- 51311.Prescher, G., et al., Chromosomal aberrations defining uveal melanoma of poor prognosis.514Lancet, 1992. **339**(8794): p. 691-2.
- 515 12. Horsman, D.E. and V.A. White, *Cytogenetic analysis of uveal melanoma. Consistent* 516 *occurrence of monosomy 3 and trisomy 8q.* Cancer, 1993. **71**(3): p. 811-9.
- 517 13. Sisley, K., et al., *Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma* 518 *correlate with prognosis.* Genes Chromosomes Cancer, 1997. **19**(1): p. 22-8.
- 519 14. White, V.A., et al., *Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma.* Cancer, 1998. **83**(2): p. 354-9.
- 521 15. Damato, B., et al., *Multiplex ligation-dependent probe amplification of uveal melanoma:* 522 *correlation with metastatic death.* Invest Ophthalmol Vis Sci, 2009. **50**(7): p. 3048-55.
- 523 16. Smit, K.N., et al., *Combined mutation and copy-number variation detection by targeted next-*524 *generation sequencing in uveal melanoma.* Mod Pathol, 2018. **31**(5): p. 763-771.
- Thornton, S., et al., *Targeted Next-Generation Sequencing of 117 Routine Clinical Samples Provides Further Insights into the Molecular Landscape of Uveal Melanoma*. Cancers (Basel),
   2020. 12(4).
- Tschentscher, F., et al., *Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities.* Cancer
  research, 2003. 63(10): p. 2578-2584.
- 53119.Zuidervaart, W., et al., Gene expression profiling identifies tumour markers potentially playing532a role in uveal melanoma development. Br J Cancer, 2003. 89(10): p. 1914-9.
- 533 20. Onken, M.D., et al., *Gene expression profiling in uveal melanoma reveals two molecular* 534 *classes and predicts metastatic death.* Cancer Res, 2004. **64**(20): p. 7205-9.
- 535 21. Robertson, A.G., et al., *Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma*. Cancer Cell, 2017. **32**(2): p. 204-220 e15.
- 53722.de Lange, M.J., et al., Heterogeneity revealed by integrated genomic analysis uncovers a538molecular switch in malignant uveal melanoma. Oncotarget, 2015. 6(35): p. 37824-35.
- de Lange, M.J., et al., Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the
  Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal
  Melanoma. Mol Cancer Res, 2018. 16(12): p. 1902-1911.
- 542 24. Alsafadi, S., et al., *Cancer-associated* SF3B1 *mutations affect alternative splicing by* 543 *promoting alternative branchpoint usage.* Nat Commun, 2016. **7**: p. 10615.
- 544 25. Field, M.G., et al., *Punctuated evolution of canonical genomic aberrations in uveal melanoma.* 545 Nat Commun, 2018. **9**(1): p. 116.
- 546 26. Karlsson, J., et al., *Molecular profiling of driver events in metastatic uveal melanoma*. Nat Commun, 2020. **11**(1): p. 1894.
- 548 27. Nell, R.J., et al., *Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.* BMC Cancer, 2021. **21**(1): p. 164.

<ul> <li>Zoutman, W.H., R.J. Nell, and P.A. van der Velden, Usage of Droplet Digital PCR (ddPCR)</li> <li>Assays for T Cell Quantification in Cancer. Methods Mol Biol, 2019. 1884: p. 1-14.</li> <li>Versluis, M., et al., Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.</li> <li>PLoS One, 2015, 10(3); p. e0116371.</li> </ul>	) ion
<ul> <li>Assays for T Cell Quantification in Cancer. Methods Mol Biol, 2019. 1884: p. 1-14.</li> <li>30. Versluis, M., et al., Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.</li> <li>PLoS One. 2015. 10(3): p. e0116371.</li> </ul>	ion
554 30. Versluis, M., et al., <i>Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.</i> 555 PLoS One, 2015, <b>10</b> (3); p. e0116371.	ion
555 PLoS One. 2015. <b>10</b> (3); p. e0116371.	ion
	ion
556 31. Nell, R.J., et al., Allele-specific digital PCR enhances precision and sensitivity in the detecti	
557 and quantification of copy number alterations in heterogeneous DNA samples: an in silico a	and
559 32 van Essen TH et al. Prognostic parameters in uveal melanoma and their association wit	th
560 BAP1 expression Br. I Ophthalmol 2014 <b>98</b> (12): p 1738-43	
561 33 Cartegri J. S.J. Chew and A.R. Krainer, Listening to silence and understanding nonsensu	<u>م</u>
562 exonic mutations that affect splicing Nat Rev Genet 2002 3(4): p 285-98	0.
563 34 Mohn F M Bubler and O Mublemann Nonsense-associated alternative splicing of T-cel	//
564 receptor beta genes: no evidence for frame dependence RNA 2005 <b>11</b> (2): p 147-56	
565 35 Repo P et al Population-based analysis of BAP1 germline variations in patients with uve	al
566 <i>melanoma</i> . Hum Mol Genet. 2019. <b>28</b> (14): p. 2415-2426.	
567 36. Niersch, J., et al., A BAP1 synonymous mutation results in exon skipping, loss of function a	and
568 <i>worse patient prognosis.</i> iScience. 2021. <b>24</b> (3): p. 102173.	
569 37. Cole, Y.C., et al., Correlation between BAP1 Localization. Driver Mutations, and Patient	
570 Survival in Uveal Melanoma, Cancers (Basel), 2022, <b>14</b> (17),	
571 38. Krug, A.K., et al., Improved EGFR mutation detection using combined exosomal RNA and	
572 <i>circulating tumor DNA in NSCLC patient plasma.</i> Ann Oncol, 2018. <b>29</b> (3): p. 700-706.	
573 39. Schoofs, K., et al., Comprehensive RNA dataset of tissue and plasma from patients with	
574 esophageal cancer or precursor lesions. Sci Data, 2022. <b>9</b> (1): p. 86.	
575 40. Albrecht, L.J., et al., Circulating cell-free messenger RNA enables non-invasive pan-tumour	r
576 monitoring of melanoma therapy independent of the mutational genotype. Clin Transl Med,	
577 2022. <b>12</b> (11): p. e1090.	
578 41. Albitar, M., et al., Combining cell-free RNA with cell-free DNA in liquid biopsy for hematolog	gic
579 and solid tumors. Heliyon, 2023. <b>9</b> (5): p. e16261.	
580 42. van Poppelen, N.M., et al., SRSF2 Mutations in Uveal Melanoma: A Preference for In-Fram	ne
581 <i>Deletions?</i> Cancers (Basel), 2019. <b>11</b> (8).	
582 43. Rodrigues, M., et al., Outlier response to anti-PD1 in uveal melanoma reveals germline MB	3D4
583 <i>mutations in hypermutated tumors.</i> Nat Commun, 2018. <b>9</b> (1): p. 1866.	
584 44. Johansson, P.A., et al., <i>Prolonged stable disease in a uveal melanoma patient with germlin</i>	1e
585 <i>MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.</i> Immunogenetics,	
586 2019. <b>71</b> (5-6): p. 433-436.	
45. Katzir, R., N. Rudberg, and K. Yizhak, <i>Estimating tumor mutational burden from RNA</i> -	
588 sequencing without a matched-normal sample. Nat Commun, 2022. <b>13</b> (1): p. 3092.	
589	